The in vitro effects of niacin on platelet biomarkers in human volunteers

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 311-317

  Serebruany, Victor ^a   Malinin, Alex ^a   Aradi, Daniel ^b   Kuliczkowski, Wiktor ^c   Norgard, Nicholas B ^d   Boden, William E ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF WROC AW   (Poland)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

In vitro; Lipids; Niacin; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; BIOLOGICAL MARKER; CD14 ANTIGEN; CD31 ANTIGEN; CD36 ANTIGEN; CD40 LIGAND; CD51 ANTIGEN; CD61 ANTIGEN; CD63 ANTIGEN; CELL SURFACE RECEPTOR; CHOLESTEROL; COLLAGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NICOTINIC ACID; PADGEM PROTEIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROTEIN GP37; PROTEIN LAMP 3; THROMBOCYTE RECEPTOR; THROMBOSPONDIN; THROMBOXANE B2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; ARTICLE; CELL MEMBRANE; DEVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; NORMAL HUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADULT; BALTIMORE; BIOLOGICAL MARKERS; BLOOD PLATELETS; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOLIPIDEMIC AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; NIACIN; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET MEMBRANE GLYCOPROTEINS; PROSTAGLANDINS;

EID: 77955454241     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0015     Document Type: Article

References (37)

1. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358.
2. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924. (Pubitemid 19101597)
3. Relou IA, Hackeng CM, Akkerman JW, et al. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 2003; 60: 961-971.
4. García-Guerra R, Mateo CR, García-Muñoz MS, et al. Distinct cholesterol and phospholipid incorporation at the platelet plasma membrane of hyperlipidemic subjects: structural order and function. Platelets 1998; 9: 365-373.
5. Ravindran R, Krishnan LK.Increased platelet cholesterol and decreased percentage volume of platelets as a secondary risk factor for coronary artery disease. Pathophysiol Haemost Thromb 2007; 36: 45-51. (Pubitemid 351373323)
6. Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol 2009; 20: 321-326.
7. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158: 429-441.
8. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101: 20B-26B.
9. Shobha H, Ganji S, Tavintharan, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45: 1835-1845.
10. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther 2009; 14: 157-169.
11. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35: 168-180.
12. Lordkipanidzé M, Diodati JG, Schampaert E, et al. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease. Am J Cardiol 2009; 104: 1189-1193.
13. Serebruany VL, Kogushi M, Dastros-Pitei D, et al. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.Thromb Haemost 2009; 102: 111-119.
14. Zeidan AM, Kouides PA, Tara MA, et al. Platelet function testing: state of the art. Expert Rev Cardiovasc Ther 2007; 5: 955-967. (Pubitemid 47499966)
15. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P - selectin? Thromb Haemost 1999; 81: 314-316.
16. Serebruany VL, Gurbel PA, O'Connor CM. Platelet Inhibition by Sertraline and N-Desmethylsertraline : A Possible Missing Link Between Depression, Coronary Events, and Mortality Benefits of Selective Serotonin Reuptake Inhibitors. Pharm Res 2001; 43: 453-462.
17. Serebruany VL, Malinin AI, Scott R. The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. J Cardiovasc Pharm Ther 2006; 11: 1-6.
18. Serebruany V, Malinin A, Goodin T, et al. The in vitro effects of Xancor, synthetic astaxanthine derivative, on hemostatic biomarkers in aspirin naïve, and aspirin treated subjects with multiple risk factors for vascular disease. Am J Ther 2010; in press.
19. Hallén J, Atar D, Serebruany V. Effects of FX06 In Vitro on Platelet, Coagulation, and Fibrinolytic Biomarkers in Volunteers and Patients With Documented Coronary Artery Disease. Am J Ther 2010; in press.
20. Serebruany VL, Malinin AI, Lowry DR, et al. Platelet Inhibition by Valsartan and Valeryl 4-hydroxy Valsartan: A Possible Missing Link to Explain Benefits of Angiotensin II Receptor Blockers in Patients After Acute Vascular Events. J Cardiovasc Pharm 2004; 43: 677-684.
21. Relou IA, Hackeng CM, Akkerman JW, et al. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 2003; 60: 961-971.
22. Mehta JL, Chen LY. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med 1996; 127: 287-295. (Pubitemid 126657309)
23. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine: nitric oxide pathway. Implications for vascular disease. J Biol Chem 1997; 272: 89-95. (Pubitemid 27021129)
24. Riddell DR, Owen JS. Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Thromb Res 1996; 81: 597-606.
25. Desai K, Bruckdorfer KR, Hutton RA, et al. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res 1989; 30: 831-840. (Pubitemid 19167305)
26. Curtiss LK, Plow EF. Interaction of plasma lipoproteins with human platelets. Blood 1984; 64: 365-374. (Pubitemid 14051321)
27. Nofer JR, Tepel M, Kehrel B, et al. High density lipoproteins enhance the Na+/H+ antiport in human platelets. Thromb Haemost 1996; 75: 635-641.
28. Nofer JR, Walter M, Kehrel B, et al. HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. Biochem Biophys Res Commun 1995; 207: 148-154.
29. Graham D, Simpson HD, Dominiczak AF, et al. In vivo and in vitro studies of the role of HDL in platelet activation in normotensive and hypertensive subjects. J Hum Hypertens 1995; 9: 753-758.
30. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-124. (Pubitemid 19101030)
31. Goldberg A. Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85: 1100-1105. (Pubitemid 30214256)
32. Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. Thromb Res 1985; 40: 543-553. (Pubitemid 16177171)
33. Vincent JE, Zijlstra FJ. Nicotinic acid inhibits thromboxane synthesis in platelets. Prostaglandins 1978; 15: 629-636. (Pubitemid 8333963)
34. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009; 63: 1369-1377.
35. Papaliodis D, Boucher W, Kempuraj D, et al. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther 2008; 327: 665-672.
36. Saareks V, Ylitalo P, Mucha I, et al. Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man. Pharmacol Toxicol 2002; 90: 338-342. (Pubitemid 34713200)
37. Pattison A, Eason CT, Bonner FW. Nicotinic acid enhances the production of 6-ketoprostaglandin F1 alpha in human whole blood in vitro. Res Commun Chem Pathol Pharmacol 1987; 55: 423-426. (Pubitemid 17050994)